Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.

Szczegóły
Abstrakt

Tytuł:: Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
Autorzy:: Cao J; Translational Medicine Laboratory, The First College of Wenzhou Medical University, Wenzhou, China.
Wu L; Department of Clinical Transfusion, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Lei X; Translational Medicine Laboratory, The First College of Wenzhou Medical University, Wenzhou, China.
Shi K; Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shi L; Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shi Y; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Źródło:: Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 673-681.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
MeSH Terms:: Carcinoma, Hepatocellular*/diagnosis
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Carcinoma, Hepatocellular*/mortality
Liver Neoplasms*/diagnosis
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Liver Neoplasms*/mortality
RNA, Long Noncoding*/analysis
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Databases, Genetic ; Female ; Genomics ; Humans ; Liver/chemistry ; Liver/metabolism ; Male ; Middle Aged ; Prognosis
References:: Cancers (Basel). 2019 Apr 05;11(4):. (PMID: 30959792)
Cancer Cell Int. 2019 May 21;19:138. (PMID: 31139015)
Mol Ther Nucleic Acids. 2020 Mar 6;19:482-497. (PMID: 31902747)
J Exp Clin Cancer Res. 2019 May 9;38(1):189. (PMID: 31072375)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Nat Med. 2015 Nov;21(11):1253-61. (PMID: 26540387)
Contemp Oncol (Pozn). 2015;19(1A):A68-77. (PMID: 25691825)
Gene. 2019 Mar 1;687:47-55. (PMID: 30415008)
Gastroenterology. 2017 Mar;152(4):745-761. (PMID: 28043904)
Methods Mol Biol. 2015;1238:65-76. (PMID: 25421655)
Mol Oncol. 2019 Oct;13(10):2246-2258. (PMID: 31368655)
Biometrics. 2000 Jun;56(2):337-44. (PMID: 10877287)
J Hepatol. 2020 Feb;72(2):215-229. (PMID: 31954487)
Br J Cancer. 2013 Jun 25;108(12):2419-25. (PMID: 23660942)
Biomed Pharmacother. 2017 Sep;93:40-47. (PMID: 28622593)
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. (PMID: 30061739)
Nucleic Acids Res. 2003 Jan 1;31(1):258-61. (PMID: 12519996)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Cell Death Dis. 2018 Jun 13;9(6):706. (PMID: 29899418)
J Proteome Res. 2019 Feb 1;18(2):623-632. (PMID: 30450911)
Nat Rev Genet. 2009 Mar;10(3):155-9. (PMID: 19188922)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Noncoding RNA Res. 2017 Dec 05;2(3-4):129-136. (PMID: 30159431)
J Cell Physiol. 2020 Apr;235(4):3928-3938. (PMID: 31608998)
Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G559-G565. (PMID: 29097358)
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. (PMID: 29115304)
Nat Rev Genet. 2009 Jan;10(1):57-63. (PMID: 19015660)
Mol Cancer. 2019 Feb 19;18(1):28. (PMID: 30782188)
Cell. 2009 Feb 20;136(4):629-41. (PMID: 19239885)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
Contributed Indexing:: Keywords: Long non-coding RNAs; The Cancer Genome Atlas; hepatocellular carcinoma; overall survival; prognosis
Substance Nomenclature:: 0 (RNA, Long Noncoding)
Entry Date(s):: Date Created: 20210224 Date Completed: 20211112 Latest Revision: 20211112
Update Code:: 20240105
PubMed Central ID:: PMC8291889
DOI:: 10.1080/21655979.2021.1878763
PMID:: 33622186
: Czasopismo naukowe

Full Text Finder

Long non-coding RNAs (lncRNAs), as one common type of non-coding RNAs, play a critical role in the tumorigenesis and development of hepatocellular carcinoma (HCC). In the current study, we aimed to assess the correlation between lncRNAs expression levels and prognosis of HCC patients. A lncRNA-based signature was also developed to predict the prognosis of HCC in this work. The lncRNAs expression profiles in tissues of tumor and para-carcinoma were obtained from The Cancer Genome Atlas (TCGA) database. The lncRNA-based prognostic model was established by least absolute shrinkage and selection operator (LASSO). The multivariate Cox-regression analysis was applied to identify the independent risk factors and subsequently developed a prognostic nomogram. Based on the co-expression analyses, we identiﬁed the lncRNA-related mRNAs and performed the biological function analysis. Between HCC and para-carcinoma tissues, 220 differentially expressed lncRNAs were filtered. Among these lncRNAs, 19 lncRNAs were identified as prognostic factors and were used to build a prognostic signature of overall survival (OS). Furthermore, a nomogram with high performance for predicting the OS of HCC patients (C-index: 0.779) by combining the 19-lncRNA signature (P < 0.001) and clinicopathologic factors including HBV (P = 0.005) and stage (P =0.017) was established. Functional enrichment analysis revealed that 19 lncRNAs had potential effects on tumor cell proliferation in HCC. In summary, we established a 19-lncRNA signature to predict the prognosis of HCC patients, which may perform a crucial role in guiding the management of HCC.

Informacja